华西医学

华西医学

oXiris-内毒素吸附技术的临床应用

查看全文

脓毒症是宿主对感染的反应失调,产生危及生命的器官损害;是重症监护病房患者死亡的主要原因。内毒素作为触发体内瀑布式炎症级联反应的源头,引起大量促炎及抗炎因子释放,在脓毒症的发病中起重要作用。因此,目前认为清除内毒素是改善脓毒症预后的有效手段。目前多黏菌素 B 吸附柱(PMX)和吸附性血滤膜(oXiris)均能吸附内毒素。该文总结了现有的体外实验、动物实验和临床试验,认为部分脓毒症患者可通过清除内毒素获益,同时根据临床专家使用 oXiris 的经验对 oXiris 的临床应用提出建议。

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection, and is the leading cause of death in intensive care unit patients due to limited therapies currently. As is known to all, endotoxin is important in the pathogenesis of sepsis, whereby infection triggers a systemic inflammatory response, resulting in release of pro- and anti-inflammatory cytokines, which are thought to be responsible for the tissue damage that occurs in sepsis patients. Therefore, removing endotoxins is considered as an effective way to improve the conditions of sepsis patients. Both Toraymaxin (PMX) and adsorptive membrane such as oXiris can remove endotoxins by adsorption, and in this review we will summarize current studies, included in vitro study, animal study, and clinical research to show the benefit from endotoxin removal by oXiris, and also give some suggestions about oXiris clinical practice from experienced experts.

关键词: 脓毒症; 内毒素; 内毒素清除; 预后; 吸附型膜材

Key words: Sepsis; Endotoxin; Endotoxin removal; Prognosis; Adsorptive membrane

引用本文: Mark R.Marshall, 张凌, 王敏敏, 刘新宇, 周昱. oXiris-内毒素吸附技术的临床应用. 华西医学, 2018, 33(7): 797-800. doi: 10.7507/1002-0179.201806041 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations. Am J Respir Crit Care Med, 2016, 193(3): 259-272.
2. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA, 2009, 301(23): 2445-2452.
3. Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care, 2017, 5: 40.
4. Rimmelé T, Assadi A, Cattenoz M, et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant, 2009, 24(2): 421-427.
5. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp, 2018, 6(1): 12.
6. Monard C, Rimmeléa T, Chuasuwan A, et al. Comparaison de duex techniques de purification sanguine extracorporelle dans un modéle de rat en choc septique. Ann Fr Anesth Reanim, 2013, 32(Suppl 1): A339-A340.
7. Candidi F, Covotta M, Caravetta P, et al. Continuous renal replacement therapy with an adsorbent membrane in postoperative septic cardiac patients: a clinical experience. EACTA, 2012: 211.
8. Turani F, Candidi F, Barchetta R, et al. Continuous renal replacement therapy with the adsorbent membrane oXiris in septic patients: a clinical experience. Crit Care, 2013, 17(Suppl 2): P63.
9. Hui WF, Chan WKY. Role of hemofilter with endotoxin adsorption capacity in management of septic shock. Crit Care Shock, 2017, 20: 119-123.
10. Prato F, Tengattini M, Tasso G, et al. Use of oXiris during continuous renal replacement therapy (CRRT) in patients with septic shock and AKI: a case series. Intensive Care Med Exp, 2017, 5(Suppl 2): 0858.
11. Mikolasevic I, Orlic L, Devčić B, et al. Application of oxiris® membrane in septic acute kidney injury due to gram-negative bacterial infection. Acta Medica Croatica, 2014: 149-155.
12. Tang KB, Chau CM, Lam KN. Effect of oXiris haemodiafiltration in shock reversal for intraabdominal sepsis and septic shock: a case control series. Intensive Care Med Exp, 2016, 4(Suppl 1): A381.
13. Shum HP, Chan KC, Kwan MC, et al. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection. Hong Kong Med J, 2013, 19(6): 491-497.
14. Cocchi E, Bonaudo R, Mattozzi F, et al. Multiorgan failure with severe rhabdomyolyis after cardiac transplant successfully treated with CRRT with AN69 heparin engrafted filter oXiris. Pediatr Nephrol, 2017, 32: 1692.
15. Turani F, Belli AB, Martni SM, et al. oXiris membrane decreases endotoxin during RRT in septic patients with basal EAA>0.6. Crit Care, 2016, 20(Suppl 2): P196.
16. Adamik BA, Smiechowicz JS, Zielinski SZ, et al. Use of extracorporeal endotoxin elimination therapy for septic shock. Crit Care, 2013, 17(Suppl 2): P66.
17. Govil, Deepak, Gupta, et al. Cytokine adsorption in sepsis: correct timing can predict the favorable outcome. Kidney Int Rep, 2017, 2: S29.
18. Musielak A, Silska M, Lipkowska K, et al. Septex® and oXiris® - new systems of blood purification in SIRS treatment in children. Pediatr Nephrol, 2012, 27: 1770.
19. Imahase H, Sakamoto Y, Kusunose M, et al. Examination of blood filtration membrane removal ability of HMGB1. Crit Care, 2012, 16(Suppl 3): P10.
20. Plata-Menchaca EP, Sabater-Riera J, Estruch M, et al. Pilot study to evaluate the use of an adsorption membrane (OXIRIS®) during cardiopulmonary bypass surgery. Intensive Care Med Exp, 2016, 4(Suppl 1): A754.
21. Caravetta P, Lappa A, Menichetti S, et al. Continuous renal replacement therapy combined with endotoxins removal in septic patients: a pilot study// 18th Annual International Conference on Continuous Renal Replacement Therapies (CRRT). San Diego: 18th International Conference on CRRT, 2013: 41.
22. Harenshi K. Inflamm Res, 2010, 59(Suppl 1): S63.
23. Martin O, Allzouchiche B, Capellier G, et al. Une nouvelle membrane préhéparinée pour hemofiltration continue en reanimation. Réanimation, 2009, 18 (Suppl 1): S17.
24. Caravetta P, Lappa A, Seven L, et al. Clinical evaluation of new CRRT membrane with endotoxins and cytokines removal proprieties. Simposio Mostra Anestesia Rianimazione E Terepia Instensiva, Milan, 2011.
25. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA, 2014, 311(13): 1308-1316.